Immunogenicity of biopharmaceuticals:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
New York, NY
Springer [u.a.]
2008
|
| Schriftenreihe: | Biotechnology: pharmaceutical aspects
8 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XI, 263 S. Ill., graph. Darst. 235 mm x 155 mm |
| ISBN: | 9780387758404 9780387758411 0387758402 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV023324984 | ||
| 003 | DE-604 | ||
| 005 | 20090529 | ||
| 007 | t | ||
| 008 | 080602s2008 ad|| |||| 00||| eng d | ||
| 015 | |a 07,N41,0597 |2 dnb | ||
| 016 | 7 | |a 985692081 |2 DE-101 | |
| 020 | |a 9780387758404 |c Gb. (Pr. in Vorb.) |9 978-0-387-75840-4 | ||
| 020 | |a 9780387758411 |9 978-0-387-75841-1 | ||
| 020 | |a 0387758402 |c Gb. (Pr. in Vorb.) |9 0-387-75840-2 | ||
| 024 | 3 | |a 9780387758404 | |
| 028 | 5 | 2 | |a 11767305 |
| 035 | |a (OCoLC)254058733 | ||
| 035 | |a (DE-599)DNB985692081 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-355 | ||
| 050 | 0 | |a QR188.4 | |
| 082 | 0 | |a 616.079 | |
| 084 | |a VS 9200 |0 (DE-625)147726:253 |2 rvk | ||
| 084 | |a XI 2222 |0 (DE-625)152983:12928 |2 rvk | ||
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a 610 |2 sdnb | ||
| 245 | 1 | 0 | |a Immunogenicity of biopharmaceuticals |c Marco van de Weert ; Eva Horn Møller |
| 264 | 1 | |a New York, NY |b Springer [u.a.] |c 2008 | |
| 300 | |a XI, 263 S. |b Ill., graph. Darst. |c 235 mm x 155 mm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Biotechnology: pharmaceutical aspects |v 8 | |
| 650 | 4 | |a Biopharmaceutics |x Immunology | |
| 650 | 4 | |a Immunological tolerance | |
| 650 | 4 | |a Pharmaceutical biotechnology | |
| 650 | 0 | 7 | |a Arzneimittel |0 (DE-588)4003115-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Immunreaktion |0 (DE-588)4133841-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelallergie |0 (DE-588)4143175-3 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 0 | 1 | |a Immunreaktion |0 (DE-588)4133841-8 |D s |
| 689 | 0 | 2 | |a Arzneimittelallergie |0 (DE-588)4143175-3 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Weert, Marco van de |e Sonstige |4 oth | |
| 700 | 1 | |a Horn Møller, Eva |e Sonstige |4 oth | |
| 830 | 0 | |a Biotechnology: pharmaceutical aspects |v 8 |w (DE-604)BV021640956 |9 8 | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016509018&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016509018 | ||
Datensatz im Suchindex
| _version_ | 1804137665582333952 |
|---|---|
| adam_text | Contents
1. Immune
Reactions Towards
Biopharmaceuticals -
a
General,
Mechanistic Overview
.......................................... 1
Camilla Foged and
Anne Sundblad
2.
Clinical Aspects of Immunogenicity to Biopharmaceuticals
........ 27
Simona Malucchi
and Antonio Bertolotto
3.
Assessment of Unwanted Immunogenicity
....................... 57
Meenu Wadhwa and Robin Thorpe
4.
Models for Prediction of Immunogenicity
........................ 75
Erwin
L
Roggen
5.
Immunogenicity of Biopharmaceuticals: Causes, Methods
to Reduce Immunogenicity, and
Biosimilars
...................... 97
Marco van
de Weert
and Eva Horn
МфИег
6.
Case Study: Immunogenicity of rhEPO
..........................113
Arno Kromminga
and Gilbert
Deroy
1.
Case Study: Immunogenicity of Interferon-Beta
..................127
Klaus Bendtzen and
Arno
Kromminga
8.
Case Study: Immunogenicity of Insulin
..........................137
Henriette Mersebach,
Fannie Smith, Thomas
Sparre
and Lisbeth Bjerring Jensen
9.
Case Study: Immunogenicity of Factor
VIII......................147
Silke
Ehrenforth and Stephanie Seremetis
10.
Case Study: Immunogenicity of Natalizumab
.....................173
Meena Subramanyam
11.
Case Study: Immunogenicity of Anti-TNF Antibodies
............189
Klaus Bendtzen
12.
Heparin-Induced Thrombocytopenia
.............................205
Carmel
A. Celestín
and John R. Bartholomew
13.
Presenting an Immunogenicity Risk Assessment to Regulatory
Agencies
......................................................239
Paul Chamberlain
Subject Index
..................................................259
|
| adam_txt |
Contents
1. Immune
Reactions Towards
Biopharmaceuticals -
a
General,
Mechanistic Overview
. 1
Camilla Foged and
Anne Sundblad
2.
Clinical Aspects of Immunogenicity to Biopharmaceuticals
. 27
Simona Malucchi
and Antonio Bertolotto
3.
Assessment of Unwanted Immunogenicity
. 57
Meenu Wadhwa and Robin Thorpe
4.
Models for Prediction of Immunogenicity
. 75
Erwin
L
Roggen
5.
Immunogenicity of Biopharmaceuticals: Causes, Methods
to Reduce Immunogenicity, and
Biosimilars
. 97
Marco van
de Weert
and Eva Horn
МфИег
6.
Case Study: Immunogenicity of rhEPO
.113
Arno Kromminga
and Gilbert
Deroy
1.
Case Study: Immunogenicity of Interferon-Beta
.127
Klaus Bendtzen and
Arno
Kromminga
8.
Case Study: Immunogenicity of Insulin
.137
Henriette Mersebach,
Fannie Smith, Thomas
Sparre
and Lisbeth Bjerring Jensen
9.
Case Study: Immunogenicity of Factor
VIII.147
Silke
Ehrenforth and Stephanie Seremetis
10.
Case Study: Immunogenicity of Natalizumab
.173
Meena Subramanyam
11.
Case Study: Immunogenicity of Anti-TNF Antibodies
.189
Klaus Bendtzen
12.
Heparin-Induced Thrombocytopenia
.205
Carmel
A. Celestín
and John R. Bartholomew
13.
Presenting an Immunogenicity Risk Assessment to Regulatory
Agencies
.239
Paul Chamberlain
Subject Index
.259 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV023324984 |
| callnumber-first | Q - Science |
| callnumber-label | QR188 |
| callnumber-raw | QR188.4 |
| callnumber-search | QR188.4 |
| callnumber-sort | QR 3188.4 |
| callnumber-subject | QR - Microbiology |
| classification_rvk | VS 9200 XI 2222 |
| ctrlnum | (OCoLC)254058733 (DE-599)DNB985692081 |
| dewey-full | 616.079 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.079 |
| dewey-search | 616.079 |
| dewey-sort | 3616.079 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| discipline_str_mv | Chemie / Pharmazie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02184nam a2200565 cb4500</leader><controlfield tag="001">BV023324984</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20090529 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">080602s2008 ad|| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">07,N41,0597</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">985692081</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780387758404</subfield><subfield code="c">Gb. (Pr. in Vorb.)</subfield><subfield code="9">978-0-387-75840-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780387758411</subfield><subfield code="9">978-0-387-75841-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0387758402</subfield><subfield code="c">Gb. (Pr. in Vorb.)</subfield><subfield code="9">0-387-75840-2</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9780387758404</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">11767305</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)254058733</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB985692081</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QR188.4</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.079</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 9200</subfield><subfield code="0">(DE-625)147726:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 2222</subfield><subfield code="0">(DE-625)152983:12928</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">15,3</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunogenicity of biopharmaceuticals</subfield><subfield code="c">Marco van de Weert ; Eva Horn Møller</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Springer [u.a.]</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XI, 263 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield><subfield code="c">235 mm x 155 mm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Biotechnology: pharmaceutical aspects</subfield><subfield code="v">8</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biopharmaceutics</subfield><subfield code="x">Immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunological tolerance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical biotechnology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immunreaktion</subfield><subfield code="0">(DE-588)4133841-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelallergie</subfield><subfield code="0">(DE-588)4143175-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Immunreaktion</subfield><subfield code="0">(DE-588)4133841-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimittelallergie</subfield><subfield code="0">(DE-588)4143175-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weert, Marco van de</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Horn Møller, Eva</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Biotechnology: pharmaceutical aspects</subfield><subfield code="v">8</subfield><subfield code="w">(DE-604)BV021640956</subfield><subfield code="9">8</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016509018&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016509018</subfield></datafield></record></collection> |
| id | DE-604.BV023324984 |
| illustrated | Illustrated |
| index_date | 2024-07-02T20:55:15Z |
| indexdate | 2024-07-09T21:15:54Z |
| institution | BVB |
| isbn | 9780387758404 9780387758411 0387758402 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016509018 |
| oclc_num | 254058733 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-355 DE-BY-UBR |
| owner_facet | DE-19 DE-BY-UBM DE-355 DE-BY-UBR |
| physical | XI, 263 S. Ill., graph. Darst. 235 mm x 155 mm |
| publishDate | 2008 |
| publishDateSearch | 2008 |
| publishDateSort | 2008 |
| publisher | Springer [u.a.] |
| record_format | marc |
| series | Biotechnology: pharmaceutical aspects |
| series2 | Biotechnology: pharmaceutical aspects |
| spelling | Immunogenicity of biopharmaceuticals Marco van de Weert ; Eva Horn Møller New York, NY Springer [u.a.] 2008 XI, 263 S. Ill., graph. Darst. 235 mm x 155 mm txt rdacontent n rdamedia nc rdacarrier Biotechnology: pharmaceutical aspects 8 Biopharmaceutics Immunology Immunological tolerance Pharmaceutical biotechnology Arzneimittel (DE-588)4003115-9 gnd rswk-swf Immunreaktion (DE-588)4133841-8 gnd rswk-swf Arzneimittelallergie (DE-588)4143175-3 gnd rswk-swf Arzneimittel (DE-588)4003115-9 s Immunreaktion (DE-588)4133841-8 s Arzneimittelallergie (DE-588)4143175-3 s DE-604 Weert, Marco van de Sonstige oth Horn Møller, Eva Sonstige oth Biotechnology: pharmaceutical aspects 8 (DE-604)BV021640956 8 Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016509018&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Immunogenicity of biopharmaceuticals Biotechnology: pharmaceutical aspects Biopharmaceutics Immunology Immunological tolerance Pharmaceutical biotechnology Arzneimittel (DE-588)4003115-9 gnd Immunreaktion (DE-588)4133841-8 gnd Arzneimittelallergie (DE-588)4143175-3 gnd |
| subject_GND | (DE-588)4003115-9 (DE-588)4133841-8 (DE-588)4143175-3 |
| title | Immunogenicity of biopharmaceuticals |
| title_auth | Immunogenicity of biopharmaceuticals |
| title_exact_search | Immunogenicity of biopharmaceuticals |
| title_exact_search_txtP | Immunogenicity of biopharmaceuticals |
| title_full | Immunogenicity of biopharmaceuticals Marco van de Weert ; Eva Horn Møller |
| title_fullStr | Immunogenicity of biopharmaceuticals Marco van de Weert ; Eva Horn Møller |
| title_full_unstemmed | Immunogenicity of biopharmaceuticals Marco van de Weert ; Eva Horn Møller |
| title_short | Immunogenicity of biopharmaceuticals |
| title_sort | immunogenicity of biopharmaceuticals |
| topic | Biopharmaceutics Immunology Immunological tolerance Pharmaceutical biotechnology Arzneimittel (DE-588)4003115-9 gnd Immunreaktion (DE-588)4133841-8 gnd Arzneimittelallergie (DE-588)4143175-3 gnd |
| topic_facet | Biopharmaceutics Immunology Immunological tolerance Pharmaceutical biotechnology Arzneimittel Immunreaktion Arzneimittelallergie |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016509018&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV021640956 |
| work_keys_str_mv | AT weertmarcovande immunogenicityofbiopharmaceuticals AT hornmøllereva immunogenicityofbiopharmaceuticals |